Stocks · Healthcare · Medical - Equipment & Services
MiniMed Group, Inc. Common Stock MMED
$20.16 +2.34% Close, Oct 5, 2026 · NASDAQ · Market cap $5.53B
Low risk
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- The company holds net cash of $148.0M (cash above total debt).
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth, 3-year CAGRTop 47%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 32%
- Gross marginBottom 38%
- Operating marginTop 42%
- Accruals (lower is better)Bottom 40%
- Net debt / EBITDA (lower is better)Top 14%
How cheap the shares are relative to earnings, cash flow and their own history.
- Free-cash-flow yieldBottom 48%
- EBITDA / enterprise valueTop 33%
- Sales / enterprise valueTop 20%
Strength and persistence of the price trend, including versus the S&P 500.
- 6-month returnTop 20%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 5%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 35%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 40%
- Maximum drawdown, 3 yearsTop 15%
- Net debt / EBITDA (lower is better)Top 14%
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Gross margin | 53.8% | — | Bottom 38% | |
| Operating margin | 0.5% | — | Top 42% | |
| Net margin | -10.2% | — | — | |
| Free-cash-flow margin | -9.8% | — | — | |
| Return on invested capital | 0.4% | — | Top 32% | |
| Revenue growth, 3-year CAGR | 11.4% | — | Top 47% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -4.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1.5%
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- -1.66×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 4.14%
- Net buyback yield (TTM)
- -9.72%
- Shareholder yield
- -5.59%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jul 31, 2026 (filed Sep 8, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 0 of 3
- Average EPS surprise, last 4
- -100.0%
- Average 2-day reaction, last 8
- +9.9%
- Positive 20 days after report
- 1 of 3
Analysts
- Consensus price target
- $25.88
- Target vs current price
- +28.4%
- Analysts with a rating
- 8
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Sep 1, 2026 | -3.3% | +10.7% | +15.1% | -1.1% | — |
| Jun 3, 2026 | -356.2% | +15.9% | +22.9% | +23.5% | +58.6% |
| Apr 17, 2026 | -194.0% | +3.0% | -2.8% | -21.0% | +7.3% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Sep 1, 2026 | $0.12 | $0.12 | -3.3% | $843.0M |
| Jun 3, 2026 | -$0.68 | -$0.15 | -356.2% | $837.0M |
| Apr 17, 2026 | -$0.16 | $0.17 | -194.0% | $790.0M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (forward) | 29.9× | — | — | — |
| EV / EBITDA | 60.5× | — | — | Top 33% |
| EV / Sales | 1.67× | — | — | Top 20% |
| Free-cash-flow yield | -5.71% | — | — | Bottom 48% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- 50-day average slope (20 days)
- +12.2%
- Distance from 50-day average
- -1.2%
- RSI (14)
- 45.7
- Relative volume
- 5.35×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 49.9%
- Current drawdown from 1-year high
- -15.4%
- Maximum drawdown, 3 years
- -41.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Mar 6, 2026 | May 15, 2026 | -41.6% | 49 days | 53 days (Aug 3, 2026) |
| Sep 3, 2026 | Sep 30, 2026 | -18.3% | 18 days | Not yet recovered |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $5.53B
- Revenue (TTM)
- $3.22B
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Revenue | $2.25B | $2.47B | $2.71B | $3.10B |
| Gross profit | $1.31B | $1.44B | $1.52B | $1.68B |
| Operating income | -$69.0M | -$69.0M | -$202.0M | $49.0M |
| Net income | -$96.0M | -$112.0M | -$250.0M | -$331.0M |
| EPS (diluted) | -$0.34 | -$0.40 | -$0.89 | -$1.29 |
| Q4 2024 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|
| Revenue | $724.0M | $752.0M | $790.0M | $837.0M | $843.0M |
| Net income | -$209.0M | -$27.0M | -$119.0M | -$183.0M | $0 |
| EPS (diluted) | — | — | -$0.42 | -$0.68 | $0.00 |
| FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|
| Operating cash flow | -$6.0M | $41.0M | $140.0M | -$197.0M |
| Capital expenditure | -$167.0M | -$148.0M | -$193.0M | -$223.0M |
| Free cash flow | -$173.0M | -$107.0M | -$53.0M | -$420.0M |
| Dividends paid | $0 | $0 | $0 | $0 |
| Net share buybacks | $0 | $0 | $0 | $538.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $207.0M
- Total assets
- $4.72B
- Total liabilities
- $1.10B
- Total debt
- $59.0M
- Net debt
- -$148.0M
- Shareholders’ equity
- $3.62B
As of Jul 31, 2026 (filed Sep 8, 2026).
Short interest
- Shares sold short
- 13,594,922
- Days to cover
- 4.85
- Change vs previous report
- +68.7%
FINRA short interest, settlement date Sep 15, 2026.